RecruitingPhase 2NCT04991454

Xenon MRI Pulm Hypertension

Xenon MRI in Pulmonary Hypertension


Sponsor

Bastiaan Driehuys

Enrollment

60 participants

Start Date

Sep 1, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study uses a special type of MRI scan with inhaled xenon gas to better understand how the lungs work in patients with pulmonary hypertension (high blood pressure in the lungs). It aims to track how this condition changes over time and how patients respond to treatment. **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with pulmonary hypertension confirmed by a heart catheterization test - Either: you are waiting for a lung transplant (Cohort 1), OR you have newly diagnosed Group 1 pulmonary arterial hypertension (Cohort 2) - You are willing and able to sign consent and attend required visits - If you are a woman who could become pregnant, you must have a negative pregnancy test before MRI **You may NOT be eligible if...** - You have severe heart disease (poor heart function or significant valve disease) - You have active cancer, sickle cell anemia, or severe liver disease (Child-Pugh C) - You are pregnant - You cannot have an MRI (metal implants, severe claustrophobia, unable to lie flat) - You have sarcoidosis (Cohort 2 only) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG129Xe Hyperpolarized

Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC), as is the case for all protocols currently carried out under IND 109,490.


Locations(1)

Duke University Medical Center

Durham, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04991454


Related Trials